FDA Approval: AJOVY (FREMANEZUMAB-VFRM) — Type 1 - New Molecular Entity
Policy FDA-BLA761089 · Neurology
Ajovy (fremanezumab-vfrm), an injectable drug approved by the FDA, is expected to receive a J-code assignment for Medicare billing. It is likely to be reimbursed under Part B, potentially utilizing an